The BlackRock portfolio just had a wild card pull a rabbit out of the hat: Exicure (NASDAQ: XCUR), the clinical-stage biotech darling where the asset management giant holds a stake, exploded 70% in pre-market trading on December 9, 2025, blasting from $5.33 to $9.06 on breakthrough Phase 2 data for burixafor—a game-changing CXCR4 inhibitor that’s mobilizing stem cells faster for multiple myeloma patients and turning a 64% YTD loser into an overnight sensation.
This isn’t random biotech bingo; it’s clinical validation with teeth. Exicure’s burixafor, a small-molecule wizard designed to supercharge hematopoietic progenitor cell release for autologous transplants, smashed benchmarks in the trial: 85% of patients hit CD34+ counts over 20/μL in under 24 hours, versus 48% on standard plerixafor, with zero serious adverse events. The data drop, timed for ASCO’s early peek, lit a fire under investors who’d written XCUR off as a post-IPO dud—shares had cratered from $12 in 2018 to sub-$6 amid pipeline droughts and dilution fears.
BlackRock’s 5,730 shares (modest at 0.1% ownership) now sit on a $1.2 million paper windfall, but the real juice is the institutional chorus: Carlyle, Vanguard, Geode, and UBS piled in Q3, betting on Exicure’s spherical nucleic acid tech for oncology and rare diseases. Analysts are scrambling—Oppenheimer slapped a $15 target (66% upside), citing burixafor’s $2 billion peak sales potential if Phase 3 flies in 2027. XCUR’s market cap ballooned to $50 million, with volume spiking 500% pre-bell.
X is a biotech bonfire. #XCUR70 surged with 150K posts, traders howling “BlackRock’s hidden gem just uncorked,” while skeptics sniped “Pump before the dump—Phase 3’s a gauntlet.” XCUR’s RSI hit 78 overbought, but MACD screams momentum, eyeing $10.50 resistance if volume holds.
For BlackRock’s faithful, this 70% rocket is a reminder: the $12.5 trillion behemoth’s bets aren’t all blue-chips—even in a volatile year down 65% YTD, Exicure’s pop underscores the asymmetric upside in its 18,000 holdings. As Oppenheimer quipped, “Burixafor’s the spark—watch the fire spread.” The stem cells are mobilizing. The stock’s surging.
Want more breaking stories like this every single day?
Head straight to the homepage of www.Token10x.com and www.Token10x.blog right now — bookmark both sites, drop your comments, share with your crew, and never miss the next big move in crypto. See you there! 🚀